Home
Live Updates
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting : comparemela.com
Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting
Ryvu PRMT5 inhibitors show potential best-in-class profiles, including a strong antiproliferative effect on MTAP-deleted cell lines and a good safety window...
Related Keywords
Warsaw ,
L67 ,
Poland ,
San Diego ,
California ,
United States ,
Polish ,
Krzysztof Brz ,
,
Agency For Enterprise Development ,
Menarini Group ,
Warsaw Stock Exchange ,
Polish Agency ,
Enterprise Development ,
Ryvu Therapeutics ,
Chief Scientific Officer ,
Novel Antitumor Agents ,
New Targets ,
Drug Delivery ,
comparemela.com © 2020. All Rights Reserved.